Clinical trials: Rejection
Viremia, Bacteremia
Treating Donors With Intravenous Immunoglobulin to Reduce Donor-Derived Infections
The goal of this clinical trial is to learn about the benefit of IVIG in donor-derived infections and the potential immunomodulatory effect on transplanted organs. The main questions it aims to answer are: 1.
- Conditions
- Viremia, Bacteremia, Acute Rejection of Renal Transplant
- Trial name
- NCT05799716
- Testing
- IVIG
- Volunteers
- 40 people
- Sponsor
- Shanghai Changzheng Hospital
Hand and Face Allotransplantation
Search Tolerance Signature in Vascularised Composite Allograft
Composite tissue allotransplants (CTA) involve transplantation of various tissues including vessels, nerves, skin, bones, and immune cells and entail a significant antigenic load.
- Trial name
- BIOCTA (NCT02055521)
- Testing
- Blood sample, biopsy
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Hospices Civils de Lyon
Heart Transplantation, Graft Rejection
ZeroHeart Biopsy - Prediction of Deceased Donor Heart Transplant Performance From Organ Donors Using Pre-Transplant Biopsies - A Pilot Study
The goal of this observational study is to evaluate whether molecular analysis of donor heart biopsies taken at the time of organ removal ("Time Zero") can help predict the future function and rejection risk of the transplanted…
- Conditions
- Heart Transplantation, Graft Rejection, Myocardial Injury, Organ Preservation
- Trial name
- ZeroHeart (NCT06982404)
- Testing
- Time Zero Donor Heart Biopsy for Molecular Analysis
- Where
- Austria
- Volunteers
- 50 people
- Sponsor
- Medical University of Vienna
Kidney Transplant Rejection, Cell-free DNA
Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant Monitoring
The goal of this observational study is to learn if the donor-derived cell-free DNA (dd-cfDNA) test can assess rejection in kidney transplant recipients. Participants will have blood and urine collected at their study visit.
- Trial name
- NCT07060716
- Testing
- donor-derived cell-free DNA test
- Where
- 10 sites in United States, Germany
- Volunteers
- 125 people
- Sponsor
- Insight Molecular Diagnostics
Chronic Obstructive Pulmonary, Idiopathic Pulmonary Fibrosis
EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection
The purpose of this study is to assess the efficacy and safety of the study drug, known as "ATG Fresenius S," which is sometimes called "EZ-2053," to prevent a lung transplant patient's body from rejecting a transplanted lung or…
- Conditions
- Chronic Obstructive Pulmonary, Idiopathic Pulmonary Fibrosis, Cystic Fibrosis, Bronchiectasis
- Trial name
- NCT00105183
- Testing
- EZ-2053, EZ-2053 5mg/kg
- Where
- 19 sites in United States, Australia and 2 more
- Volunteers
- 223 people
- Sponsor
- Neovii Biotech
Cardiac Transplantation
Non Invasive Detection of Cardiac Allograft Rejection by Circulating microRNAs
The purpose of this study is to evaluate the level of expression of 4 circulating microRNAs in the serum using RT-PCR. A pilote study with cardiac transplant patients has shown that expression of these microRNAs could…
- Trial name
- MIRRACLE (NCT02672683)
- Where
- France
- Volunteers
- 461 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Heart Transplant Rejection
A New Biomarker for the Non-invasive Diagnosis of Rejection After Heart Transplantation
This study is a prospective, observational multi-center cohort study. The study will consist of patients undergoing heart transplantation.
- Trial name
- BIODRAFT (NCT03477383)
- Testing
- donor-derived cell-free DNA (dd-cfDNA)
- Where
- 4 sites in Sweden
- Volunteers
- 134 people
- Sponsor
- Vastra Gotaland Region
Kidney Transplant Rejection
Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation
This study will evaluate the safety and efficacy of AT-1501 compared with tacrolimus in patients undergoing kidney transplantation.
- Trial name
- NCT05983770
- Testing
- AT-1501, Tacrolimus
- Where
- 43 sites in United States, Australia and 5 more
- Volunteers
- 127 people
- Sponsor
- Eledon Pharmaceuticals
Kidney Transplantation
rATG Versus rATG Combined With Intravenous Immunoglobulin (IVIG) Induction Immunosuppression in HLA Incompatible Transplantation (INHIBIT)
This study aims to prove similar efficacy of PE/rATG (intervention) and PE/rATG/IVIG (centre standard of care) induction regimens to prevent biopsy proven antibody-mediated changes and TCMR as composite endpoint within 12 months…
- Trial name
- INHIBIT (NCT04302805)
- Testing
- Privigen, Thymoglobulin, Plasma Exchange
- Where
- Czechia
- Volunteers
- 17 people
- Sponsor
- Institute for Clinical and Experimental Medicine
Organ Transplant Failure or Rejection, Brain Death
Calcineurin Inhibitor in NEuRoloGically Deceased Donors to Decrease Kidney delaYed Graft Function (CINERGY)
The investigators hypothesize that preconditioning neurologically deceased organ donors with the calcineurin inhibitor tacrolimus will improve short and long-term transplant survival without causing harm.
- Conditions
- Organ Transplant Failure or Rejection, Brain Death, Ischemic Reperfusion Injury
- Trial name
- CINERGY (NCT05148715)
- Testing
- Tacrolimus
- Where
- 9 sites in Canada
- Volunteers
- 414 people
- Sponsor
- Université de Sherbrooke
Kidney Transplantation
Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients
This study was to compare CFZ533 to tacrolimus (TAC) in prevention of organ rejection in kidney transplant.
- Trial name
- CIRRUS I (NCT03663335)
- Testing
- CFZ533 - Cohort 1/Cohort 2, Mycophenolate Mofetil (MMF), Corticosteroids (CS)
- Where
- 74 sites in United States, Argentina and 18 more
- Volunteers
- 418 people
- Sponsor
- Novartis Pharmaceuticals
Corneal Graft Rejection
Evaluation of the Efficacy of 2% Cyclosporine in Preventing Graft Rejection
Aim/ Objective: Study consists of 2 separate and distinct entities A. Evaluation of the efficacy of 2% cyclosporine in preventing graft rejection in primary grafts w/o high risk characteristics study 1 (PKP study) B.
- Trial name
- NCT02206789
- Testing
- Prednisolone acetate1%,, Prednisolone acetate1%, cyclosporine 2%
- Where
- India
- Volunteers
- 200 people
- Sponsor
- Aravind Eye Care System
Renal Disease
Ides in Highly Sensitized (HS) Patients Awaiting Kidney Transplantation
This is a single center phase I/II open label, exploratory study assessing safety and efficacy of IdeS® (Hansa Medical, Lund, Sweden) given immediately prior to kidney transplantation.
- Trial name
- NCT02426684
- Testing
- IdeS® (Imlifidase)
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Cedars-Sinai Medical Center
Heart Transplant Failure and Rejection, Heart Transplant
Brazilian Clinical Registry of Heart Transplantation
Prospective cohort clinical study, registry-based, multicenter, national, with the consecutive inclusion of patients with a history of Heart Transplantation in Brazil.
- Trial name
- HESTIA (NCT06453148)
- Testing
- Non-interventions
- Where
- Brazil
- Volunteers
- 730 people
- Sponsor
- Hospital Israelita Albert Einstein
Renal Transplant Rejection
Calcineurin Activity in Renal Recipients
The purpose is to define if calcineurin activity is a better biological parameter than blood concentration for the therapeutic tacrolimus monitoring.
- Trial name
- NCT01413685
- Testing
- Pharmacokinetics/dynamics
- Where
- France
- Volunteers
- 23 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Kidney Transplantation
Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant
The efficacy and safety of FTY720 is being evaluated in patients who receive a kidney transplant.
- Trial name
- NCT00099749
- Testing
- FTY 720
- Where
- 5 sites in United States
- Volunteers
- 255 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Transplantation, Renal Transplantation
A Study to Evaluate FK778 in Kidney Transplant Patients
A dose finding study to evaluate the safety and effectiveness of FK778 in kidney transplant patients
- Conditions
- Kidney Transplantation, Renal Transplantation, Transplantation, Renal, Transplantation, Kidney
- Trial name
- NCT00189735
- Testing
- FK778
- Where
- 37 sites in Austria, Belgium and 10 more
- Volunteers
- 364 people
- Sponsor
- Astellas Pharma Inc
Heart Transplant Rejection
Molecular Evidence of Rejection Intervention Trial
MERIT is a double-blind, multi-center, placebo-controlled, randomized clinical trial. Heart transplant recipients with dual-positive GEP/dd-cfDNA assays with a corresponding negative biopsy between 2 months and 2 years…
- Trial name
- MERIT (NCT07905599)
- Testing
- Prednisone
- Volunteers
- 200 people
- Sponsor
- CareDx
Blood Disease, Platelet Refractoriness
HPA Antibodies and the Distribution of Antigen and Antibodies
By detecting platelet antibodies of participants and then further to identify their genotype and analyzing laboratory examination, the investigators will obtain positive frequency of HPA antibodies, the distribution of HPA…
- Conditions
- Blood Disease, Platelet Refractoriness, Antibody-mediated Rejection
- Trial name
- NCT03408158
- Testing
- same type infusion of main HPA antigen
- Where
- China
- Volunteers
- 6,170 people
- Sponsor
- Guangzhou First People's Hospital
Kidney Transplantation, Kidney Disease
Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients
Alemtuzumab is a man-made antibody used to treat certain blood disorders. This study will evaluate treatment of kidney transplant recipients with alemtuzumab and other immune system suppressing medications with or without…
- Conditions
- Kidney Transplantation, Kidney Disease, Kidney Failure
- Trial name
- NCT00183248
- Testing
- Alemtuzumab, Mycophenolate mofetil, Sirolimus
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Miami